RJF Laboratorio Reig Jofre, S.A.
Laboratorio Reig Jofre, S.A., a pharmaceutical company, researches, develops, manufactures, and markets pharmaceutical products, raw materials, biotechnological products, nutritional supplements, health products, medical devices, cosmetics, parapharmaceuticals, food, and other products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Laboratorio Reig Jofre (BME: RJF)
›
Laboratorio Reig Jofre (BME: RJF) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,400 employees.
The shares were at 2.620 EUR on 19 November 2026, down 3.3% over 52 weeks. Its 52-week range is 2.320 EUR to 2.940 EUR: the price is 10.9% below the high and 12.9% above the low.
At a market capitalisation of 215.05M EUR, it trades at 52.4 times trailing earnings and 52.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 112% for RJF. It pays a dividend yielding 0.92% (it pays out 30% of its earnings), against a median of 1.90% among the dividend payers in that peer group.
Laboratorio Reig Jofre reports return on equity of 2.3%, an operating margin of -0.2% and revenue down 2.8% year over year.
Its debt exceeds its cash by 109.30M EUR, a debt-to-equity ratio of 0.42. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.